Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance

Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a c...

ver descrição completa

Detalhes bibliográficos
Autor principal: Leonardo-Sousa, Carlota (author)
Outros Autores: Carvalho, Andreia Neves (author), Guedes, Romina A. (author), Fernandes, Pedro M. P. (author), Aniceto, Natália (author), Salvador, Jorge A. R. (author), Gama, Maria João (author), Guedes, Rita C. (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
ubiquitin–proteasome pathway
proteasome inhibitors
mechanisms of resistance
innate resistance
acquired resistance
multiple myeloma
cancer
Adult
Bortezomib
Humans
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Quality of Life
Antineoplastic Agents
Multiple Myeloma
Neoplasms
Texto completo:http://hdl.handle.net/10316/103390
País:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/103390

Texto Completo

http://hdl.handle.net/10316/103390

Registos relacionados